The Impact of Initial Gefitinib or Erlotinib versus Chemotherapy on Central Nervous System Progression in Advanced Non–Small Cell Lung Cancer with <i>EGFR</i> Mutations

The Impact of Initial Gefitinib or Erlotinib versus Chemotherapy on Central Nervous System Progression in Advanced Non–Small Cell Lung Cancer with <i>EGFR</i> Mutations

This retrospective study was undertaken to investigate the impact of initial gefitinib or erlotinib (EGFR tyrosine kinase inhibitor, EGFR-TKI) versus chemotherapy on the risk of central nervous system (CNS) progression in advanced non-small cell lung cancer (NSCLC) with EGFR mutations.Patients with...

Full description

Saved in:
Bibliographic Details
Main Authors: Stéphanie Héon, Beow Y. Yeap, Neal I. Lindeman, Victoria A. Joshi, Mohit Butaney, Gregory Joseph Britt, Daniel B. Costa, Michael S. Rabin, David M. Jackman, Bruce E. Johnson
Format: Artigo
Language:English
Published: 2012
Online Access:https://doi.org/10.1158/1078-0432.ccr-12-0357
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1158/1078-0432.ccr-12-0357

Similar Items